Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...
A study led by MD Anderson found the investigational drug quizartinib prolongs overall survival for patients with a deadly form of acute myeloid...
A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the TRACTION platform inhibits a vital metabolic process required for cancer cells’ growth and survival.
IACS-10759 is the first small molecule drug to be developed from concept to clinical trial by MD Anderson’s Therapeutics Discovery team, which includes IACS and the CCCT. Therapeutics Discovery is a unique group of clinicians...
The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia...
Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T...